Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Krystal Biotech, Inc. operates as a biopharmaceutical company. The Company develops a proprietary gene therapy platform for the patients suffering from rare debilitating disorders. Krystal Biotech serves patients in the State of Pennsylvania.
Website: krystalbio.com



Growth: Good revenue growth rate 16.7%, there is slowdown compared to average historical growth rates 116.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +43.6%. On average the margin is improving steadily. Gross margin is high, +94.2%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.24 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 285.1% higher than minimum and 4.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 8.1x by EV / Sales multiple , the company can be 49.0% overvalued

Insiders: For the last 3 months insiders sold company shares on $22.0 mln (-0.345% of cap.)

Key Financials (Download financials)

Ticker: KRYS
Share price, USD:  (0.0%)278.75
year average price 181.34  


year start price 154.53 2025-02-10

min close price 123.36 2025-05-28

max close price 291.93 2026-01-13

current price 278.75 2026-02-09
Common stocks: 28 953 000

Dividend Yield:  0.0%
FCF Yield LTM: 1.7%
EV / LTM EBITDA: 36.6x
EV / EBITDA annualized: 42.7x
Last revenue growth (y/y):  +16.7%
Last growth of EBITDA (y/y):  +79.2%
Historical revenue growth:  +116.0%
Historical growth of EBITDA:  +106.6%
EV / Sales: 15.9x
Margin (EBITDA LTM / Revenue): 43.6%
Fundamental value created in LTM:
Market Cap ($m): 8 071
Net Debt ($m): -722
EV (Enterprise Value): 7 349
Price to Book: 7.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-26zacks.com

Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable

2026-01-23zacks.com

Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice

2026-01-16seekingalpha.com

Krystal Biotech: Beyond VYJUVEK Commercialization

2026-01-12zacks.com

KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives

2025-11-16seekingalpha.com

Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth

2025-11-03seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

2025-08-22seekingalpha.com

Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update

2025-08-21globenewswire.com

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

2025-08-04seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

2025-08-04zacks.com

Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-03 2025-08-04 2024-11-04 2024-08-05 2024-05-06 2023-11-06 2023-08-07 2023-05-08 2022-11-07
acceptedDate 2025-11-03 07:03:58 2025-08-04 07:04:06 2025-02-19 07:19:55 2024-11-04 08:05:26 2024-08-05 08:08:09 2024-05-06 08:17:38 2024-02-26 07:49:58 2023-11-06 07:08:53 2023-08-07 07:07:31 2023-05-08 08:25:12 2023-02-27 07:14:24 2022-11-07 07:11:56 2022-02-28 07:30:44 2021-03-01 08:21:14
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY
revenue 98M 96M 291M 84M 70M 45M 51M 9M 0 0 0 0 0 0
costOfRevenue 6M 7M 20M 7M 8M 2M 3M 223 000 1M 0 0 0 0 2M
grossProfit 92M 89M 270M 77M 62M 43M 48M 8M -1M 0 0 0 0 -2M
grossProfitRatio 0.942 0.925 0.92 0.886 0.947 0.974 0 0 0
researchAndDevelopmentExpenses 13M 14M 54M 14M 16M 11M 46M 11M 12M 12M 42M 12M 28M 18M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 24M 26M 24M 78M 20M 40M 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 38M 35M 114M 29M 26M 26M 98M 24M 26M 24M 78M 20M 40M 13M
otherExpenses 0 0 38M 13M 19M 15M 13M 223 000 0 13M 25M 0 0 0
operatingExpenses 51M 50M 205M 55M 41M 37M 157M 35M 38M 36M 145M 31M 68M 31M
costAndExpenses 56M 57M 225M 61M 49M 39M 160M 35M 38M 36M 145M 31M 68M 33M
interestIncome 7M 7M 30M 0 7M 8M 23M 7M 5M 4M 5M 2M 197 000 832 000
interestExpense 0 0 0 0 0 0 0 0 0 25M 0 2M 1M 0
depreciationAndAmortization 2M 2M 7M 2M 2M 2M 6M 826 000 1M 26M 3M 3M 2M 2M
ebitda 50M 41M 110M 31M 18M 20M -91M -26M -37M -23M -117M -29M -66M -30M
ebitdaratio 0.507 0.425 0.373 0.328 0.44 -3.038 0 0 0
operatingIncome 41M 39M 66M 22M 21M -7M -110M -26M -38M -49M -145M -31M -68M -33M
operatingIncomeRatio 0.423 0.409 0.268 0.3 -0.148 -3.038 0 0 0
totalOtherIncomeExpensesNet 7M 7M 30M 7M -5M -13M 123M 107M 5M 4M 5M 2M -1M 832 000
incomeBeforeTax 48M 47M 95M 30M 16M 932 000 13M 81M -33M -45M -140M -30M -70M -32M
incomeBeforeTaxRatio 0.49 0.487 0.355 0.228 0.021 9.437 0 0 0
incomeTaxExpense -31M 8M 6M 3M 477 000 5M 2M -826 000 0 0 0 -2M 0 0
netIncome 79M 38M 89M 27M 16M 932 000 11M 81M -33M -45M -140M -28M -70M -32M
netIncomeRatio 0.812 0.399 0.324 0.222 0.021 9.437 0 0 0
eps 2.741 1.33 3.12 0.95 0.54 0.03 0.4 2.88 -1.25 -1.76 -5.49 -1.1 -3.13 -1.71
epsdiluted 2.66 1.29 0.91 0.53 0.03 2.79 -1.25 -1.76 -1.1
weightedAverageShsOut 29M 29M 29M 29M 29M 28M 27M 28M 27M 26M 25M 26M 22M 19M
weightedAverageShsOutDil 30M 30M 30M 30M 30M 29M 28M 29M 27M 26M 25M 26M 22M 19M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-26 2023-02-27 2022-02-28 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 30M 23M 5M -1M 832 000
ebit 103M -97M -120M -68M -32M
nonOperatingIncomeExcludingInterest -38M -13M -25M -197 000 -832 000
netIncomeFromContinuingOperations 89M 11M -140M -70M -32M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 89M 11M -140M -70M -32M
epsDiluted 3 0.39 -5.49 -3.13 -1.71

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-03 2025-08-04 2024-11-04 2024-08-05 2024-05-06 2023-11-06 2023-08-07 2023-05-08 2022-11-07
acceptedDate 2025-11-03 07:03:58 2025-08-04 07:04:06 2025-02-19 07:19:55 2024-11-04 08:05:26 2024-08-05 08:08:09 2024-05-06 08:17:38 2024-02-26 07:49:58 2023-11-06 07:08:53 2023-08-07 07:07:31 2023-05-08 08:25:12 2023-02-27 07:14:24 2022-11-07 07:11:56 2022-02-28 07:30:44 2021-03-01 08:21:14
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY
cashAndCashEquivalents 393M 354M 345M 374M 346M 359M 358M 373M 276M 141M 162M 186M 341M 268M
shortTermInvestments 338M 328M 253M 214M 214M 179M 174M 189M 202M 210M 217M 208M 97M 3M
cashAndShortTermInvestments 731M 682M 598M 588M 560M 538M 532M 562M 478M 350M 379M 394M 438M 271M
netReceivables 130M 111M 105M 97M 103M 46M 42M 9M 0 0 0 0 0 0
inventory 38M 31M 27M 19M 12M 11M 7M 5M 0 0 0 0 0 0
otherCurrentAssets 27M 17M 13M 9M 8M 6M 7M 5M 6M 5M 5M 3M 0 0
totalCurrentAssets 926M 841M 742M 713M 683M 602M 588M 582M 484M 355M 384M 398M 442M 275M
propertyPlantEquipmentNet 156M 158M 161M 163M 165M 167M 168M 171M 171M 171M 170M 166M 120M 34M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 133M 139M 152M 106M 69M 84M 62M 37M 28M 5M 5M 13M 64M 0
taxAssets 25M 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 333 000 197 000 231 000 203 000 125 999 196 000 263 000 285 000 285 000 402 000 324 000 205 000 74 000 2M
totalNonCurrentAssets 314M 297M 314M 269M 235M 251M 230M 208M 200M 176M 175M 179M 184M 36M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 1 240M 1 138M 1 056M 982M 918M 853M 818M 790M 684M 532M 558M 576M 626M 311M
accountPayables 2M 7M 5M 6M 5M 5M 2M 4M 4M 4M 4M 6M 8M 2M
shortTermDebt 2M 2M 0 1M 3M 1M 0 2M 2M 2M 0 2M 0 0
taxPayables 0 8M 4M 573 000 709 000 2M 2M 152 000 22 000 51 000 43 000 122 000 83 000 40 000
deferredRevenue 0 0 0 0 0 38M 0 19M 17M 0 0 0 0 0
otherCurrentLiabilities 87M 70M 2M 82M 63M 3M 17M 2M 652 000 29M 267 000 21M 87 000 26 000
totalCurrentLiabilities 91M 87M 102M 90M 72M 48M 33M 28M 24M 35M 29M 28M 26M 15M
longTermDebt 8M 8M 0 6M 6M 6M 0 7M 7M 7M 0 8M 0 0
deferredRevenueNonCurrent 0 0 0 0 -588 000 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 3M 3M 1M 761 000 588 000 0 0 0 0 0 0 267 000 0 0
totalNonCurrentLiabilities 11M 11M 7M 7M 7M 6M 7M 7M 7M 7M 7M 8M 7M 3M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 10M 10M 7M 6M 8M 8M 8M 8M 9M 9M 9M 9M 8M 12M
totalLiabilities 102M 98M 109M 96M 79M 54M 40M 34M 31M 42M 36M 36M 33M 19M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
retainedEarnings -27M -107M -181M -226M -253M -269M -270M -279M -359M -326M -281M -249M -141M -71M
accumulatedOtherComprehensiveIncomeLoss 1M 1M -190 000 2M -634 000 -299 000 638 000 -382 000 -236 000 -154 000 -728 000 -1M -163 000 6000
othertotalStockholdersEquity 1 164M 1 146M 1 110M 1 093M 1 068M 1 035M 1 013M 816M 791M
totalStockholdersEquity 1 138M 1 041M 946M 886M 839M 799M 779M 756M 653M 490M 522M 541M 594M 292M
totalEquity 1 138M 1 041M 946M 886M 839M 799M 779M 756M 653M 490M 522M 541M 594M 292M
totalLiabilitiesAndStockholdersEquity 1 240M 1 138M 982M 918M 853M 790M 684M 532M 576M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 240M 1 138M 1 056M 982M 918M 853M 818M 790M 684M 532M 558M 576M 626M 311M
totalInvestments 472M 467M 405M 320M 283M 263M 236M 225M 230M 215M 222M 221M 161M 3M
totalDebt 10M 10M 7M 1M 8M 8M 8M 8M 9M 9M 9M 9M 8M 12M
netDebt -383M -344M -338M -373M -338M -351M -350M -365M -267M -132M -153M -177M -333M -257M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-26 2023-02-27 2022-02-28 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 105M 42M 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 4M 4M
totalPayables 9M 6M 4M 8M 2M
otherPayables 4M 4M 43 000 83 000 40 000
accruedExpenses 89M 9M 23M 16M 5M
capitalLeaseObligationsCurrent 1M 1M 2M 1M 8M
capitalLeaseObligationsNonCurrent 6M 7M 7M 7M 3M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 127M 1 048M 804M 735M 363M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-03 2025-08-04 2024-11-04 2024-08-05 2024-05-06 2023-11-06 2023-08-07 2023-05-08 2022-11-07
acceptedDate 2025-11-03 07:03:58 2025-08-04 07:04:06 2025-02-19 07:19:55 2024-11-04 08:05:26 2024-08-05 08:08:09 2024-05-06 08:17:38 2024-02-26 07:49:58 2023-11-06 07:08:53 2023-08-07 07:07:31 2023-05-08 08:25:12 2023-02-27 07:14:24 2022-11-07 07:11:56 2022-02-28 07:30:44 2021-03-01 08:21:14
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY
netIncome 79M 38M 89M 27M 16M 932 000 11M 81M -33M -45M -140M -30M -70M -32M
depreciationAndAmortization 2M 2M 7M 1M 2M 2M 5M 826 000 1M 705 000 4M 975 000 3M 2M
deferredIncomeTax -25M 0 0 0 0 0 0 -100M 0 0 0 0 0 0
stockBasedCompensation 0 14M 49M 13M 13M 9M 40M 8M 11M 10M 33M 9M 15M 3M
changeInWorkingCapital -28M 494 000 -14M 18M -33M 6M -38M -9M -12M 9M 3M 164 000 2M 928 000
accountsReceivables -18M -8M -63M 6M -57M -4M -42M 0 0 0 0 0 0 0
inventory -5M 880 000 -12M -4M 530 000 -2M -4M 0 0 0 0 0 0 0
accountsPayables -4M 4M 1M 91 000 784 000 727 000 -101 000 -360 000 374 000 107 000 -1M -340 000 712 000 783 000
otherWorkingCapital -1M 4M 59M 16M 22M 12M 9M -9M -12M -107 000 4M 504 000 1M 145 000
otherNonCashItems 11M -2M -7M -1M 71M -238 000 -107M -2M -2M -605 000 -690 000 -36 000 1M 33 000
netCashProvidedByOperatingActivities 40M 53M 123M 59M -4M 16M -89M -21M -34M -26M -101M -20M -48M -26M
investmentsInPropertyPlantAndEquipment -2M -2M -4M -1M -1M -1M -12M -2M -3M -5M -53M -14M -68M -15M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -98M -114M -458M -113M -113M -88M -509M -106M -174M -146M -319M -67M -190M -3M
salesMaturitiesOfInvestments 96M 105M 299M 79M 95M 64M 503M 113M 161M 155M 258M 67M 32M 7M
otherInvestingActivites 0 0 0 0 0 100M 0 0 0
netCashUsedForInvestingActivites -4M -11M -34M -19M -26M 105M -16M 4M -15M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 4M 2M 3M 11M 16M 13M 185M 2M 2M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -5000 0 3M 11M -5M 0 0 -749 000 0
netCashUsedProvidedByFinancingActivities 4M 2M 3M 11M 11M 13M 185M 1M 2M
effectOfForexChangesOnCash -307 000 1M -458 000 286 000 -337 000 187 000 -156 000 12 000 8000 -36 000 -41 000 0 0 0
netChangeInCash 39M 45M -13M 28M -13M 678 000 196M 97M 135M -21M -179M -32M 73M 81M
cashAtEndOfPeriod 393M 354M 345M 374M 346M 359M 358M 373M 276M 141M 162M 186M 341M 268M
cashAtBeginningOfPeriod 354M 309M 358M 346M 359M 358M 162M 276M 141M 162M 341M 219M 268M 188M
operatingCashFlow 40M 53M 123M 59M -4M 16M -89M -21M -34M -26M -101M -20M -48M -26M
capitalExpenditure -2M -2M -4M -1M -1M -1M -12M -2M -3M -5M -53M -14M -68M -15M
freeCashFlow 38M 51M 119M 58M -5M 15M -101M -23M -37M -32M -154M -34M -116M -41M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-26 2023-02-27 2022-02-28 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 100M 0 0 0
netCashProvidedByInvestingActivities -163M 83M -114M -227M -11M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 32M 203M 36M 356M 118M
netCommonStockIssuance 32M 203M 36M 356M 118M
commonStockIssuance 32M 203M 36M 356M 118M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -5M -749 000 -649 000 -8M 0
netCashProvidedByFinancingActivities 27M 203M 35M 348M 118M
incomeTaxesPaid 6M 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-03 ET (fiscal 2025 q3)
2025 q2
2025-08-04 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-19 ET (fiscal 2024 q4)
2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q1
2024-05-06 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)

SEC forms

Show financial reports only

SEC form 8
2025-11-03 07:04 ET
Krystal Biotech published news for 2025 q3
SEC form 8
2025-11-03 07:04 ET
Krystal Biotech published news for 2025 q3
SEC form 10
2025-11-03 07:03 ET
Krystal Biotech reported for 2025 q3
SEC form 8
2025-08-04 11:09 ET
Krystal Biotech published news for 2025 q2
SEC form 8
2025-08-04 11:09 ET
Krystal Biotech published news for 2025 q2
SEC form 10
2025-08-04 11:04 ET
Krystal Biotech reported for 2025 q2
SEC form 8
2025-05-06 12:09 ET
Krystal Biotech published news for 2025 q1
SEC form 8
2025-05-06 12:09 ET
Krystal Biotech published news for 2025 q1
SEC form 10
2025-05-06 12:08 ET
Krystal Biotech reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Krystal Biotech published news for 2025 q1
SEC form 10
2025-02-19 00:00 ET
Krystal Biotech reported for 2024 q4
SEC form 10
2024-11-04 08:05 ET
Krystal Biotech reported for 2024 q3
SEC form 8
2024-11-04 08:04 ET
Krystal Biotech published news for 2024 q3
SEC form 8
2024-11-04 08:04 ET
Krystal Biotech published news for 2024 q3
SEC form 10
2024-08-05 08:08 ET
Krystal Biotech reported for 2024 q2
SEC form 8
2024-08-05 08:03 ET
Krystal Biotech published news for 2024 q2
SEC form 8
2024-08-05 08:03 ET
Krystal Biotech published news for 2024 q2
SEC form 10
2024-08-05 00:00 ET
Krystal Biotech published news for 2024 q2
SEC form 10
2024-05-06 08:17 ET
Krystal Biotech published news for 2024 q1
SEC form 8
2024-05-06 08:04 ET
Krystal Biotech published news for 2024 q1
SEC form 8
2024-05-06 08:04 ET
Krystal Biotech reported for 2024 q1
SEC form 10
2024-05-06 00:00 ET
Krystal Biotech published news for 2024 q1
SEC form 8
2024-02-26 08:04 ET
Krystal Biotech published news for 2023 q4
SEC form 8
2024-02-26 08:04 ET
Krystal Biotech published news for 2023 q4
SEC form 10
2024-02-26 07:49 ET
Krystal Biotech reported for 2023 q4
SEC form 10
2024-02-26 00:00 ET
Krystal Biotech published news for 2023 q4
SEC form 8
2023-11-06 07:10 ET
Krystal Biotech reported for 2023 q3
SEC form 10
2023-11-06 07:08 ET
Krystal Biotech reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Krystal Biotech reported for 2023 q3
SEC form 6
2023-08-07 08:18 ET
Krystal Biotech published news for 2023 q2
SEC form 6
2023-08-07 07:13 ET
Krystal Biotech reported for 2023 q2
SEC form 10
2023-08-07 07:07 ET
Krystal Biotech reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Krystal Biotech reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Krystal Biotech reported for 2023 q2
SEC form 6
2023-07-26 16:01 ET
Krystal Biotech published news for 2023 q2
SEC form 10
2023-05-08 00:00 ET
Krystal Biotech reported for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Krystal Biotech reported for 2023 q1
SEC form 6
2023-03-09 18:26 ET
Krystal Biotech published news for 2022 q4
SEC form 6
2023-03-06 16:33 ET
Krystal Biotech published news for 2022 q4
SEC form 6
2023-02-27 07:25 ET
Krystal Biotech reported for 2022 q4
SEC form 10
2023-02-27 07:14 ET
Krystal Biotech reported for 2022 q4
SEC form 10
2023-02-27 00:00 ET
Krystal Biotech reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Krystal Biotech reported for 2022 q4
SEC form 6
2023-01-09 08:55 ET
Krystal Biotech published news for 2022 q4
SEC form 6
2022-11-17 08:33 ET
Krystal Biotech published news for 2022 q3
SEC form 6
2022-11-07 16:14 ET
Krystal Biotech reported for 2022 q3
SEC form 10
2022-11-07 07:11 ET
Krystal Biotech reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Krystal Biotech reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Krystal Biotech reported for 2022 q3
SEC form 6
2022-11-03 16:52 ET
Krystal Biotech published news for 2022 q3
SEC form 6
2022-08-18 17:02 ET
Krystal Biotech published news for 2022 q2
SEC form 6
2022-08-08 16:30 ET
Krystal Biotech reported for 2022 q2
SEC form 10
2022-08-08 07:50 ET
Krystal Biotech reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Krystal Biotech reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
Krystal Biotech reported for 2022 q2
SEC form 6
2022-06-22 08:41 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-26 16:34 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-23 16:20 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-20 08:26 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-09 16:19 ET
Krystal Biotech reported for 2022 q1
SEC form 10
2022-05-09 16:07 ET
Krystal Biotech reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Krystal Biotech reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Krystal Biotech reported for 2022 q1
SEC form 6
2022-04-07 16:14 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-03-28 16:06 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-03-22 16:40 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-03-15 16:14 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-02-28 17:11 ET
Krystal Biotech published news for 2021 q4
SEC form 10
2022-02-28 07:30 ET
Krystal Biotech published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Krystal Biotech reported for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-01-18 16:06 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2021-12-03 16:05 ET
Krystal Biotech published news for 2021 q3
SEC form 6
2021-11-29 16:06 ET
Krystal Biotech published news for 2021 q3
SEC form 6
2021-11-08 16:43 ET
Krystal Biotech published news for 2021 q3
SEC form 10
2021-11-08 07:10 ET
Krystal Biotech published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Krystal Biotech reported for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Krystal Biotech published news for 2021 q3
SEC form 6
2021-09-16 16:33 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-08-19 16:49 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-08-09 16:02 ET
Krystal Biotech published news for 2021 q2
SEC form 10
2021-08-09 08:07 ET
Krystal Biotech reported for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Krystal Biotech published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-08-02 16:39 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-07-07 16:41 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-07-01 17:31 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-05-24 16:05 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-05-11 19:31 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-05-10 08:20 ET
Krystal Biotech published news for 2021 q1
SEC form 10
2021-05-10 08:06 ET
Krystal Biotech published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Krystal Biotech reported for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-04-06 16:30 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-03-24 07:00 ET
Krystal Biotech published news for 2020 q4
SEC form 10
2021-03-01 08:21 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-03-01 08:15 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-02-05 16:39 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-02-02 16:01 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-07 08:02 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-05 17:05 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-05 17:03 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-04 08:15 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2020-12-31 17:28 ET
Krystal Biotech published news for 2020 q3
SEC form 6
2020-11-09 08:32 ET
Krystal Biotech published news for 2020 q3
SEC form 10
2020-11-06 18:41 ET
Krystal Biotech published news for 2020 q3
SEC form 6
2020-10-01 16:06 ET
Krystal Biotech published news for 2020 q3